Ditemukan 1612 dokumen dengan kata kunci 4049 |
Simpan CSV  |
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensivedisease- small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
|
|
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
|
|
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
|
|
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human am integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
|
|
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
|
|
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
|
|
Predictors of immunological failure and determinants of suboptimal CD4 testing among adults with HIV on first-line antiretroviral therapy in Andhra Pradesh, India, 2008–2011
|
No. Panggil: Transactions of The Royal Society of Tropical Medicine and Hygiene;Volume 109 No.5 Mei 2015 p 325–333 |
|
Koleksi: Artikel Internasional - Oxford ::
Cari yang mirip ::
Tambahkan ke Favorit ::
|
|
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
|
|
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
|
|
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
|
|